Evaluation of BM cytomorphology after allo-SCT in patients with MDS

摘要

Evaluation of disease status in myelodysplastic syndromes (MDS) includes assessment of blast count, dysplasia and cellularity by BM cytomorphology. In stem cell recipients with AML, we described dysplasia to be a frequent but nonspecific feature after allogeneic haematopoietic SCT on day 30 and day 100. Yet, we found normal cellularity by cytomorphology on day 30 to be associated with positive prognosis in these patients. As dysplasia and aberrant cellularity are hallmarks of MDS, we analysed the distribution and potential prognostic impact of these features by cytomorphology in BM aspirates taken on day 100 post transplant. We evaluated 25 MDS and chronic myelomonocytic leukaemia (CMML) patients (11 female, 14 male, median age 58 years, range 28-73 years) in CR at day 100 after SCT. Patients mainly suffered refractory anaemia with excess blasts-2 (RAEB-2, n = 11, 44%). Mostly, they were cytogenetically favourable risk (n = 19, 76%), each 3/25 patients (12%) had either an intermediate or an unfavourable karyotype according to the International Prognostic Scoring System.